Cytoreduction plus low‐dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high‐risk essential thrombocythaemia: an observational study
Open Access
- 12 April 2013
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 161 (6) , 865-871
Abstract
Summary: The effectiveness of low‐dose aspirin in the primary prevention of thrombosis in patients with high‐risk essential thrombocythaemia (ET) treated with cytoreductive drugs is not well established. The risk‐benefit balance of low‐dose aspirin plus cytoreductive therapy compared with cytoreduction alone was retrospectively analysed in 247 patients with high‐risk ET without prior thrombosis. Follow‐up was 763 and 685 person‐years for cytoreduction plus low‐dose aspirin and cytoreduction alone, respectively. The rate of thrombosis was not significantly reduced in patients on cytoreduction plus aspirin (14·4 events per 1000 person‐years) when compared with those on cytoreduction alone (24·8 events per 1000 person‐years; P = 0·2). However, in the subgroup of patients older than 60 years, the addition of low‐dose aspirin was associated with a significantly lower rate of thrombosis (8·6 vs. 29·2 thrombosis per 1000 person‐years for combined treatment and cytoreduction alone, respectively, P = 0·02). The rate of major bleeding was significantly higher with combined therapy than with cytoreduction alone both in the whole series (14·4 vs. 1·4 haemorrhagic events per 1000 person‐years, respectively, P = 0·006) and in the subgroup of patients older than 60 years. In conclusion, low‐dose aspirin benefits high‐risk ET patients older than 60 years receiving cytoreductive therapy as primary prophylaxis of thrombosis.Keywords
This publication has 18 references indexed in Scilit:
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)Blood, 2012
- Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic reviewThrombosis Research, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelBlood, 2007
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemiaBritish Journal of Haematology, 2005
- Efficacy and Safety of Low-Dose Aspirin in Polycythemia VeraNew England Journal of Medicine, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Acquired von Willebrand Disease in Patients with High Platelet CountsSeminars in Thrombosis and Hemostasis, 1997
- Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of ThrombosisNew England Journal of Medicine, 1995